- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02553824
FDA Approved Medication to Reduce Binge Eating and/or Purging
Qsymia (Phentermine-topiramate) to Reduce Binge Eating/Purging in Patients With Bulimia Nervosa and Binge Eating Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bulimia nervosa (BN) and binge eating disorder (BED) are serious mental disorders associated with adverse psychological and physical consequences. Treatment options to date offer limited success, leaving at least 50-70% of patients still symptomatic after treatment. The purpose of the study is to evaluate whether phentermine-topiramate (Qsymia), a medication currently FDA approved for the treatment of obesity, will demonstrate efficacy-compared to placebo- when re-purposed for patients with bulimia and binge eating.
Participants will be randomized into one of two conditions: qsymia or Placebo. One condition will receive 3 months of phentermine-topiramate, a 2 week washout, then 3 months of placebo. The other condition will receive 3 months of Placebo, a 2 week washout, then 3 months of phentermine-topiramate. Participants will receive a total of 6 months of treatment and then have a 2 month follow-up off of medications.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford School of Medicine, Psychiatry and Behavioral Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must meet Diagnostic and Statistical Manual -Edition 5 criteria for bulimia or binge eating disorder, which has not responded to prior treatment
- Men and women between the ages of 18-60
- Must be at least normal weight (i.e. body mass index at least 21.0 or greater)
- If female of child-bearing potential, the participant must have an initial negative pregnancy test and be taking adequate birth control
- must be medically stable with no new diagnoses (medical, surgical, or psychiatric) within the past 6 months
- Must live close enough or be within commute distance of study site (Stanford, CA) to be able to comply with study visits, treatment plans, and blood draws and other possible assessments (i.e. EKG)
Exclusion Criteria:
- Any patient with bipolar disease or schizophrenia or any patient taking a mood stabilizer or antipsychotic medication within the past 3 months
- Any patient with current or past history of anorexia nervosa (i.e., with a Body mass index of < 17.5).
- Any patient with prior (within 30 days) use of Over The Counter (OTC) weight-reducing agents, herbal preparations
- Any patient who has been prescribed a medication for weight loss within the past 3 months
- Any psychological weight-loss interventions (i.e., Weight Watchers, Jenny Craig) in which patient has lost weight over the past month (unless willing to discontinue).
- Any patient currently in therapy with a psychostimulant or who has used a psychostimulant within the past 6 months
- Any patient with known sensitivity to phentermine or topiramate
- Any patient who has had a change in thyroid, psychiatric, or blood pressure medications within the past one month
- Any patient who is taking a potassium-wasting diuretic
- Any patient who is on a carbonic anhydrase inhibitor such as zonisamide acetazolamide, or dichlorphenamide
- Any diabetic who is taking insulin or an insulin secretagogue
- Any patient with liver enzymes at baseline greater than three times the upper limit of normal
- Any patient with a baseline potassium of less than 3.0 millequivalent/Liter. Patients with baseline potassium levels between 3.0-3.5 miliEquivalents/Liter will be encouraged to ingest high potassium foods such as bananas, oranges, or tomato juice daily during the study
- Any patient with abnormal baseline thyroid test or with a Thyroid Stimulating Hormone (TSH) greater than 1.5 times the upper limit of normal
- Any patient who is unwilling or expresses uncertainty about being able to refrain from daily alcohol use (even if at moderate levels) or illegal drugs while taking the study medication.
- Any adult with recent history of suspected alcohol or substance abuse or substance dependence
- Any patient who regularly uses marijuana (including medical marijuana) or illegal drugs
- Any patient who has a history of addiction to a stimulant
- Any patient who expresses current suicidal ideation
- Any patient with a history of nephrolithiasis
- Any patient who is pregnant or who is planning to become pregnant during the study period.
- Any patient who is currently participating in any other clinical study that involves an active treatment
- Any patient who is unable to identify a primary care physician
- Any patient with a history of cardiovascular disease (i.e. recent history of Myocardial Infarction, stroke, shortness of breath, chest pain) that could increase vulnerability to the sympathomimetic effects of a stimulant like drug. If clinical suspicion is high, baseline EKG will be obtained and anyone with abnormal findings will be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phentermine/Topiramate-First + Placebo
Patients randomly assigned to this condition will receive the study medication first, have a 2 week washout, and then crossover to receive the control medication/placebo
|
Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning.
For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
Other Names:
Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout.
They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning.
For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
Other Names:
|
Placebo Comparator: Placebo-First + Phentermine/Topiramate
Patients randomly assigned to this condition will receive the control medication (placebo) first followed by a 2 week washout, and then receive the study medication.
|
Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning.
For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
Other Names:
Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout.
They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning.
For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of binge eating episodes as measured by the Eating Disorder Examination Assessment
Time Frame: 8.5 months
|
The primary outcome is the frequency of binge episodes
|
8.5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of binge eating episodes measured by the Eating Disorder Examination Assessment
Time Frame: 8.5 months
|
Frequency of binge episodes
|
8.5 months
|
Percentage of Abstinence from Binge Eating as Measured by the Eating Disorder Examination Assessment
Time Frame: 8.5 months
|
Percentage of patients who have had no binge episodes as assessed by the EDE
|
8.5 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Debra L Safer, MD, Stanford University
- Principal Investigator: Sarah Adler, PsyD, Stanford University
- Principal Investigator: Shebani Sethi, MD, Stanford University
Publications and helpful links
General Publications
- Safer DL, Adler S, Dalai SS, Bentley JP, Toyama H, Pajarito S, Najarian T. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa. Int J Eat Disord. 2020 Feb;53(2):266-277. doi: 10.1002/eat.23192. Epub 2019 Nov 13.
- Dalai SS, Adler S, Najarian T, Safer DL. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa. Contemp Clin Trials. 2018 Jan;64:173-178. doi: 10.1016/j.cct.2017.10.007. Epub 2017 Oct 14.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Signs and Symptoms, Digestive
- Hyperphagia
- Bulimia
- Feeding and Eating Disorders
- Binge-Eating Disorder
- Bulimia Nervosa
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anticonvulsants
- Appetite Depressants
- Anti-Obesity Agents
- Central Nervous System Stimulants
- Sympathomimetics
- Topiramate
- Phentermine
Other Study ID Numbers
- 31390
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bulimia Nervosa
-
University of California, San DiegoRecruitingAnorexia Nervosa | Bulimia Nervosa | Atypical Anorexia Nervosa | Atypical Bulimia NervosaUnited States
-
Linnaeus UniversityGöteborg University; Linkoeping UniversityRecruitingBulimia Nervosa | Major Depression | Anorexia Nervosa/BulimiaSweden
-
Yeshiva UniversityYale UniversityRecruitingAnorexia Nervosa | Bulimia Nervosa | Anorexia Nervosa, Atypical | Bulimia; AtypicalUnited States
-
University Hospital, ToulouseUnknownAnorexia Nervosa/BulimiaFrance
-
Maastricht UniversityZonMw: The Netherlands Organisation for Health Research and Development; Utrecht... and other collaboratorsRecruitingAnorexia Nervosa | Bulimia Nervosa | Atypical Anorexia Nervosa (Other Specified Eating Disorder) | Atypical Bulimia Nervosa (Other Specified Eating Disorder)Netherlands
-
Washington University School of MedicineNational Institute of Mental Health (NIMH)Completed
-
Rosemary Claire RodenChildren's Miracle NetworkEnrolling by invitationBulimia Nervosa | Impulsive Behavior | Purging (Eating Disorders) | Eating Disorders | Eating Disorders in Adolescence | Anorexia Nervosa/Bulimia | Anorexia in Adolescence | Anorexia Nervosa, Atypical | Anorexia Nervosa, Binge Eating/Purging TypeUnited States
-
University Health Network, TorontoKlarman Family FoundationCompletedAnorexia Nervosa | Bulimia Nervosa
-
Drexel UniversityNational Institute of Mental Health (NIMH)Active, not recruitingBinge-Eating Disorder | Bulimia Nervosa | Binge Eating | Bulimia; Atypical | Binge-Eating and Purging Type Anorexia NervosaUnited States
-
University Health Network, TorontoTerminatedAnorexia Nervosa | Bulimia NervosaCanada
Clinical Trials on Phentermine/Topiramate-First
-
University of California, San DiegoRecruitingObesity | Colitis, UlcerativeUnited States
-
VIVUS LLCSynteract, Inc.; SentrxCompletedDiabetesUnited States
-
VIVUS LLCCovance; SentrxCompletedHepatic ImpairmentUnited States
-
University of MinnesotaRecruitingPediatric ObesityUnited States
-
VIVUS LLCMedpace, Inc.Completed
-
University of MinnesotaRecruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Denver Health and Hospital AuthorityCompleted
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
VIVUS LLCCompleted